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How does the level of BCG vaccine protection against
tuberculosis fall over time?
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Ibrahim Abubakar consultant epidemiologist 2
1Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London; 2Tuberculosis Section, Health Protection
Agency, Colindale, London and Norwich Medical School, University of East Anglia, Norwich
This is one of a series of occasional articles that highlight areas of
practice where management lacks convincing supporting evidence. The
series adviser is David Tovey, editor in chief, the Cochrane Library. This
paper is based on a research priority identified and commissioned by
the National Institute for Health Research’s Health Technology
Assessment programme on an important clinical uncertainty. To suggest
a topic for this series, please email us at uncertainties@bmj.com
WHO estimates that in 2009, 9.4 million people developed
tuberculosis and 1.7 million died of the disease worldwide. 1 In
the UK, incidence has risen over the past two decades; most
cases are in vulnerable groups such as migrants, people who
are homeless, or those with a history of imprisonment.2Bacillus
Calmette Guérin (BCG) vaccine offers 70-80% efficacy against
severe forms of tuberculosis in childhood, particularlymeningitis
in infancy.3 4 When given later in life, efficacy against
tuberculosis (which, in adults, commonly presents as pulmonary
disease) varies in different regions of the world, for reasons that
are not clearly understood.3 5 The failure of BCG to protect
adults in some populations—in particular in some studies in
India6—has sometimes been wrongly generalised to suggest
that BCG never protects against pulmonary disease. However,
the Medical Research Council trial established that use of BCG
in school age children in the UK was highly effective against
tuberculosis (80%).7
On the basis of criteria from the International Union Against
Tuberculosis and Lung Disease,8 universal BCG vaccination of
school children with a negative tuberculin skin test (aimed at
preventing the peak of tuberculosis in young adults in the UK)
was discontinued in 2005. Current policy recommends
vaccination in infancy of children in high risk groups to prevent
severe forms of childhood tuberculosis,9 10 and this practice is
cost effective.4 Uncertainty remains, however, about how long
the protection afforded by BCG vaccination lasts.11 This
uncertainty has implications for the cost effectiveness of
vaccination at later ages and for the role of a new vaccine.
An intensive search is in progress for a new vaccine that would
work under circumstances in which BCG does not, possibly
used together with BCG, or as a booster after BCG, with 12
candidates currently being evaluated.12 The process of
development, testing, and delivery of a new vaccine requires a
thorough understanding of the mechanism behind protection
against tuberculosis, including reasons for variation in
protection, duration of protection, and the magnitude of waning,
and whether previous BCG vaccination might interfere with the
action of a new vaccine.13
What is the evidence of uncertainty?
We searched Pubmed and Embase for articles and systematic
reviews on the duration of protection by BCG. This analysis is
limited to a selection of studies with relevance to UK policy
based on a previous systematic review11 and our knowledge of
the general literature on BCG efficacy. The previous systematic
review, which included nine randomised controlled trials of
high quality, found no evidence of substantial protection against
tuberculosis after 10 years from BCG vaccination.13 Lack of
evidence of protection, of course, is not the same as evidence
of lack of protection. However, we note from recently published
data the possibility of longer BCG protection: additional
comprehensive follow-up of a trial in North American Indians
found that protection against disease of about 50% was present
40-50 years after vaccination.14 A cohort study in Brazil with
good follow-up found efficacy of 48%, 15-20 years after
neonatal BCG vaccination.15Other studies that were not included
in the previous systematic review contained further relevant
evidence. Of particular interest is a case-population study in the
UK, in which information about BCG vaccination or absence
of previous latent tuberculosis was available for people with
tuberculosis and for the general population, allowing comparison
of disease rates in a vaccinated and an unvaccinated uninfected
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cohort. This study showed 59% protection at 10-15 years after
vaccination at school age.16
Is ongoing research likely to provide
evidence?
A search of the Cochrane database and of clinical trials registers
(WHO’s international clinical trials registry platform, which
includes several national databases, current controlled trials,
and the UKCRNportfolio database) did not identify any ongoing
or recently completed trials. A Cochrane systematic review
entitled Infant Bacillus Calmette-Guerin (BCG) Immunisation
and Duration of Protection Against Tuberculosiswas registered
in 2008, but we found no accompanying protocol or published
review.
There are two ongoing projects commissioned by the National
Institute for Health Research (Health Technology Assessment):
a new systematic review of all trials and observational studies;
and a series of case-control studies undertaken to estimate BCG
protection against tuberculosis in the UK, up to 25 years after
school age vaccination and up to 17 years after neonatal
vaccination. Although case-control studies can be vulnerable
to selection and information bias, this approach addresses the
research question in the shortest possible time in countries with
a low burden of tuberculosis.
What should we do in the light of
uncertainty?
Clinicians should be aware of and support the current policy of
infant BCG vaccination for those at higher risk.10 The best
estimate of duration of protection by BCG is currently about
10 years, with recent data suggesting that the vaccine may
protect for longer, although the level of protection seems to fall
with time. People vaccinated 10 years or more before coming
into close contact with infectious tuberculosis might have no
BCG derived protection against active disease. BCG does not
protect when given to people who are already infected, and
revaccination of individuals after initial vaccination does not
seem to offer substantial additional protection.17 We therefore
do not recommend repeat vaccination, even in people travelling
to countries with a high tuberculosis burden.
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Recommendation for further research
Populations—Adults and children at risk of tuberculosis
Interventions—BCG vaccination
Comparisons—Vaccinated and unvaccinated individuals in a randomised controlled trial, but the sample size required
would be too high given the relatively low incidence of TB in the UK; there are also ethical issues. Alternatively, cases
of tuberculosis and controls in a case-control design. In high burden countries, a cohort design may be feasible (although
there would be ethical issues) but would require a long period of follow-up, by which time a new vaccine might be
available.
Outcome—Level of BCG protection against active tuberculosis with time since vaccination
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